What Combioxin S.A. does

Combioxin S.A. is a clinical-stage biotechnology company founded in 2015 and headquartered in Epalinges, canton of Vaud, Switzerland. The company develops first-in-class therapeutics for critically ill patients, built around two distinct pipeline assets. Its lead asset, CAL02, is a broad-spectrum anti-virulence agent that uses proprietary engineered liposomes to capture and neutralize toxins produced by both Gram-positive and Gram-negative virulent bacteria; CAL02 is currently in a global Phase 2b clinical study for severe community-acquired bacterial pneumonia (SCAP). The second program targets immunoparalysis — acquired immune deficiency in ICU patients, particularly sepsis sufferers — via a disease-modifying approach intended to restore immune homeostasis without triggering hyperinflammation.

The business model is asset-light and partner-led: Combioxin has signed a worldwide out-licensing agreement with Eagle Pharmaceuticals covering the commercial rights to CAL02, with Combioxin positioned to receive licensing and royalty economics upon commercialization. CAL02 carries FDA Fast-Track and Qualified Infectious Disease Product (QIDP) designations (granted June 2023), and the first-in-human data set was published in The Lancet Infectious Diseases (Laterre PF et al., 2019). Capital formation has been predominantly non-dilutive — a CHF 1.1M Innosuisse grant (joint with the University of Bern, June 2026) for the immunoparalysis program, plus prior support from the Foundation for Innovation and Technology (FIT) and MassChallenge. The leadership team comprises co-founders Samareh Azeredo da Silveira Lajaunias (Managing Director) and Frédéric Lajaunias (Founder & Managing Director), with Toni Perez serving as Chief Medical Officer.

Name

Combioxin S.A.

Legal name

Combioxin S.A.

Website

https://combioxin.com

Company type

Private

Founded year

2015

Operating status

Operating

Headcount range

1–10 employees

Short description

Combioxin S.A. is a clinical-stage Swiss biotechnology company developing first-in-class therapeutics for critically ill patients, including CAL02 (an engineered liposome anti-virulence agent for severe bacterial pneumonia, Phase 2b) and an immunoparalysis treatment for ICU patients with acquired immune deficiency.

Ownership category

akta.pro rank

Product category

Infectious Disease and Critical Care Therapeutics

NAICS

Medical Laboratories (621511), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Biological Products, (No Disgnostic Substances) (2836), Services-Commercial Physical & Biological Research (8731), Services-Medical Laboratories (8071), In Vitro & In Vivo Diagnostic Substances (2835)

akta.pro primary industry

Microbiology & Infectious Disease Diagnostics (culture, rapid antigen, syndromic panels) (HLAAALAC)

akta.pro secondary industry

Therapeutic Peptides & Protein/Peptide Biologics (HLAAAAAH)

Keywords

• Anti-virulence therapeutics
• Infectious disease drugs
• Clinical-stage biotechnology
• Liposome drug delivery
• Immune homeostasis therapy

Headquarters

HQ city

Geneva

HQ country

Switzerland

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Licensing Royalties: Worldwide out-licensing agreement signed with Eagle Pharmaceuticals for commercial rights to CAL02. Combioxin receives licensing/royalty payments as a clinical-stage biotech company developing first-in-class drugs.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels3 records

Core offering

Combioxin S.A. is a clinical-stage biotechnology company developing first-in-class drug candidates for critically ill patients. Its lead asset, CAL02, is a broad-spectrum anti-virulence agent built on proprietary engineered liposomes that capture and neutralize bacterial toxins from both Gram-positive and Gram-negative pathogens, currently in a global Phase 2b study for severe community-acquired bacterial pneumonia. Its second pipeline program targets acquired immune deficiency (immunoparalysis) in ICU patients through a disease-modifying approach designed to restore immune homeostasis.

Product overview

Combioxin is a clinical-stage biotechnology company developing first-in-class life-saving drugs for critically ill patients. The company has two distinct products in its pipeline: CAL02, a broad-spectrum anti-virulence agent utilizing proprietary engineered liposome technology for treating severe community-acquired bacterial pneumonia, and an immunoparalysis treatment targeting acquired immune deficiency in critically ill patients by restoring immune homeostasis. CAL02 has received FDA QIDP and Fast-Track designations and is currently in a global Phase 2b clinical study, with worldwide out-licensing rights held by Eagle Pharmaceuticals.

Differentiator

Problem solved

Functional benefit

Quantifiable outcome

• Clinical results published in Lancet Infectious Diseases demonstrate CAL02's potential to revolutionize treatment standards while dramatically reducing recovery time and healthcare costs (Laterre PF et al. 2019; 19(6):620-630)

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature2 records

Partnerships

Two partnerships are on record, tiered core.

• University of BerncoreStrategic or Co-development Partner · 11 June 2026Combioxin and University of Bern jointly received CHF 1.1 million from Swiss Innovation Agency Innosuisse for development of a novel drug to treat acquired immune deficiency in critically ill patients. This academic-industry partnership combines Combioxin's drug development expertise with University of Bern's research capabilities.
• Eagle PharmaceuticalscoreOEM/ Whitelabel/ Licensing PartnerWorldwide out-licensing agreement signed with Eagle Pharmaceuticals for commercial rights to CAL02. Eagle Pharmaceuticals gains exclusive rights to commercialize the anti-virulence agent for severe community-acquired bacterial pneumonia, leveraging their commercial infrastructure and regulatory experience in the pharmaceutical market.

Scale indicators3 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Aridis Pharmaceuticals: Clinical-stage biotech developing anti-infective monoclonal antibodies for severe bacterial and viral infections, including pneumonia. Directly comparable as a small clinical-stage anti-infective company pursuing licensing-led commercialization.
• Inotrem: Clinical-stage biotech developing TREM-1-targeting immunomodulatory therapeutics for septic shock and acute inflammatory conditions. Directly comparable to Combioxin's immunoparalysis program, addressing immune dysregulation in critically ill patients.
• Nabriva Therapeutics: Clinical/commercial-stage company developing antibiotics for serious and life-threatening respiratory infections, including community-acquired bacterial pneumonia. Comparable to Combioxin as a small anti-infective company addressing severe pneumonia.
• Motif Bio: Clinical-stage anti-infective company developing next-generation antibiotics for serious bacterial infections, including Gram-positive pneumonia. Directly comparable as a small clinical-stage anti-infective drug developer.

Broad incumbents

• Eagle Pharmaceuticals: Specialty pharmaceutical company that has out-licensed CAL02 commercialization rights globally. Comparable as Combioxin's commercialization partner for critical-care injectable drugs and as a broader player in hospital anti-infectives.
• Paratek Pharmaceuticals: Specialty pharma focused on antibiotics for serious community-acquired infections, including pneumonia. Comparable as a broader specialty anti-infective player operating in the same severe pneumonia indication as CAL02.

Emerging players

• Iterum Therapeutics: Clinical-stage company developing oral and IV antibiotics for resistant Gram-negative and Gram-positive infections. Comparable as a peer anti-infective developer targeting serious bacterial infections.
• CytoSorbents: Commercial-stage company with blood-purification therapies targeting cytokine storm and inflammation in critically ill and ICU patients. Comparable to Combioxin's immunoparalysis program through its focus on immune modulation in critical care.
• Adrenomed: Clinical-stage biotech developing Adrenomedullin-targeted therapy for septic shock and acute heart failure in critically ill patients. Comparable to Combioxin's immunoparalysis program via an ICU/sepsis focus.
• AM-Pharma: Clinical-stage biotech developing alkaline phosphatase for sepsis-associated acute kidney injury in critically ill patients. Comparable as an ICU-focused, mechanism-novel biotech addressing unmet needs in critical care.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds3 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Combioxin S.A.